Cargando…

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients

AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Zifu, Lin, Anqi, Yi, Yonglin, Shen, Weitao, Zhang, Jian, Luo, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172928/
https://www.ncbi.nlm.nih.gov/pubmed/35685767
http://dx.doi.org/10.2147/DDDT.S363665
_version_ 1784721934115667968
author Yao, Zifu
Lin, Anqi
Yi, Yonglin
Shen, Weitao
Zhang, Jian
Luo, Peng
author_facet Yao, Zifu
Lin, Anqi
Yi, Yonglin
Shen, Weitao
Zhang, Jian
Luo, Peng
author_sort Yao, Zifu
collection PubMed
description AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance within this cohort. PATIENTS AND METHODS: We analyzed the gene mutations significantly associated with the OS from 2 cohorts of SCLC platinum-treated patients. And then we screened out THSD7B mutation. In order to understand the mechanism between THSD7B mutation and platinum resistance, we designed gene mutation co-occurrence and mutual exclusivity analysis, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) analysis, and Connectivity Map (CMap) analysis. RESULTS: The poor prognosis of THSD7B mutant patients may be related to the inhibition of cell death-related pathways, the up-regulation of cell invasion and metastasis pathways, and the down-regulation of immune response pathways. Lovastatin and cyclooxygenase inhibitors could be used as potential target compounds in THSD7B mutant patients, which provides reference for future research on platinum resistance. CONCLUSION: THSD7B can be considered a reliable biomarker that effectively facilitates the prediction of poor survival in SCLC platinum-treated patients.
format Online
Article
Text
id pubmed-9172928
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-91729282022-06-08 THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients Yao, Zifu Lin, Anqi Yi, Yonglin Shen, Weitao Zhang, Jian Luo, Peng Drug Des Devel Ther Original Research AIM: Several cases of small cell lung cancer (SCLC) patients demonstrate resistance to the treatment initiatives such as cisplatin after platinum chemotherapy. It is crucial to the improvement of the overall survival (OS) of SCLC patients to discover the gene mutation inducing platinum resistance within this cohort. PATIENTS AND METHODS: We analyzed the gene mutations significantly associated with the OS from 2 cohorts of SCLC platinum-treated patients. And then we screened out THSD7B mutation. In order to understand the mechanism between THSD7B mutation and platinum resistance, we designed gene mutation co-occurrence and mutual exclusivity analysis, gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) analysis, and Connectivity Map (CMap) analysis. RESULTS: The poor prognosis of THSD7B mutant patients may be related to the inhibition of cell death-related pathways, the up-regulation of cell invasion and metastasis pathways, and the down-regulation of immune response pathways. Lovastatin and cyclooxygenase inhibitors could be used as potential target compounds in THSD7B mutant patients, which provides reference for future research on platinum resistance. CONCLUSION: THSD7B can be considered a reliable biomarker that effectively facilitates the prediction of poor survival in SCLC platinum-treated patients. Dove 2022-06-03 /pmc/articles/PMC9172928/ /pubmed/35685767 http://dx.doi.org/10.2147/DDDT.S363665 Text en © 2022 Yao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yao, Zifu
Lin, Anqi
Yi, Yonglin
Shen, Weitao
Zhang, Jian
Luo, Peng
THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title_full THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title_fullStr THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title_full_unstemmed THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title_short THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients
title_sort thsd7b mutation induces platinum resistance in small cell lung cancer patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172928/
https://www.ncbi.nlm.nih.gov/pubmed/35685767
http://dx.doi.org/10.2147/DDDT.S363665
work_keys_str_mv AT yaozifu thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients
AT linanqi thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients
AT yiyonglin thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients
AT shenweitao thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients
AT zhangjian thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients
AT luopeng thsd7bmutationinducesplatinumresistanceinsmallcelllungcancerpatients